VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer - Brain Metastasis
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Observational [Patient Registry]
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: bevacizumab, standard chemotherapy and radiation
Type: Other
Overall Status
Recruiting
Summary
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
Detailed Description
1. non small cell lung cancer (non squamous carcinoma)

2. ECOG 0-1

3. from 18-75 years old
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- non squamous cell non small cell lung cancer

- with measurable disease

- ECOG 0-1

Exclusion Criteria:

- patients received surgery in recent 4 weeks
Location
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Status: Recruiting
Contact: Li Liu, MD - 027-85872015 - liulixiehe@163.com
Start Date
June 2013
Completion Date
December 2018
Sponsors
Li Liu
Source
Huazhong University of Science and Technology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page